Sean Maduck - 02 Jun 2025 Form 4 Insider Report for CORCEPT THERAPEUTICS INC (CORT)

Role
Officer
Signature
/s/ Joseph Douglas Lyon, as attorney-in-fact for Sean Maduck
Issuer symbol
CORT
Transactions as of
02 Jun 2025
Net transactions value
-$1,417,035
Form type
4
Filing time
04 Jun 2025, 20:33:11 UTC
Previous filing
05 May 2025
Next filing
05 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Maduck Sean Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 101 REDWOOD SHORES PARKWAY, REDWOOD CITY /s/ Joseph Douglas Lyon, as attorney-in-fact for Sean Maduck 04 Jun 2025 0001698310

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CORT Common Stock Award $63,652 +888 +5.6% $71.68 16,817 02 Jun 2025 Direct F1, F2, F3
transaction CORT Common Stock Award $0 +888 +5.3% $0.000000 17,705 02 Jun 2025 Direct F3, F4
transaction CORT Common Stock Award $101,000 +20,000 +113% $5.05 37,705 02 Jun 2025 Direct F3
transaction CORT Common Stock Sale $448,139 -5,752 -15% $77.91 31,953 02 Jun 2025 Direct F3, F5, F6
transaction CORT Common Stock Sale $488,311 -6,191 -19% $78.87 25,762 02 Jun 2025 Direct F3, F5, F7
transaction CORT Common Stock Sale $498,967 -6,246 -24% $79.89 19,516 02 Jun 2025 Direct F3, F5, F8
transaction CORT Common Stock Sale $146,269 -1,811 -9.3% $80.77 17,705 02 Jun 2025 Direct F3, F5, F9
holding CORT Common Stock 89,693 02 Jun 2025 See Footnote F10
holding CORT Common Stock 10,000 02 Jun 2025 See Footnote F11

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CORT Stock option (right to buy) Options Exercise $0 -20,000 -24% $0.000000 61,986 02 Jun 2025 Common Stock 20,000 $5.05 Direct F12
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on June 2, 2025.
F2 In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
F3 Includes 458 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on September 3, 2024, 265 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 2, 2024 and 266 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 3, 2025. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
F4 Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.
F5 This transaction was made pursuant to a 10b5-1 plan adopted by the Reporting Person on September 5, 2024 in effect at the time of this transaction.
F6 Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $77.56 to $78.515 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F7 Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $78.57 to $79.5675 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F8 Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $79.5725 to $80.535 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F9 Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $80.585 to $81.00 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.
F10 Represents the shares held by Sean and Molly Maduck Living Trust of which the Reporting Person is a co-trustee.
F11 Represents the shares held by Duckhill Capital, LLC of which the Reporting Person is President and disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
F12 Fully exercisable.

Remarks:

President, Corcept Endocrinology The power of attorney under which this form was signed is on file with the Commission.